Treatment characteristics of HIV patients with lymphoma
. | HIV score 0 . | . | HIV score 1 . | . | HIV score 2-3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | ACVBP . | CHOP . | CHOP . | Ld-CHOP . | Ld-CHOP . | VS . | |||
| Median anthracycline DI (range) | 0.91* (0.1-1.1) | 0.98* (0.5-1.2) | 0.96 (0.4-1.8) | 0.96 (0.1-1.4) | 0.97 (0.6-1.2) | NA | |||
| Below 0.80, no. (%) | 32 (29)* | 4 (4)* | 9 (9) | 8 (10) | 5 (10) | NA | |||
| Median cyclophosphamide DI (range) | 0.91 (0.1-1.1) | 0.98 (0.5-1.2) | 0.96 (0.2-1.9) | 0.96 (0.1-1.3) | 0.99 (0.7-1.2) | NA | |||
| Below 0.80, no. (%) | 33 (30)* | 5 (5)* | 8 (8) | 8 (10) | 4 (8) | NA | |||
| G-CSF prophylaxis, no (%) | 97 (89) | 95 (87) | 60 (63) | 42 (51) | 25 (51) | NA | |||
| Toxicity grade 3-4, no. (%) | |||||||||
| Platelets | 50 (46)* | 13 (12)* | 23 (24) | 11 (13) | 1 (22) | 5 (12) | |||
| Leukocytes | 82 (75)* | 39 (36)* | 49 (52)* | 25 (30)* | 20 (41)* | 5 (12)* | |||
| Infection | 28 (26)* | 6 (6)* | 15 (16) | 11 (13) | 12 (24) | 7 (17) | |||
| Mucositis | 21 (19)† | 9 (8)† | 2 (2) | 1 (1) | 1 (2) | 0 (0) | |||
| Response to chemotherapy, no. (%) | |||||||||
| CR/CRu | 66 (61) | 56 (51) | 47 (49)† | 26 (32)† | 10 (20)* | 2 (5)† | |||
| PR | 17 (16) | 16 (15) | 9 (9) | 13 (16) | 6 (12) | 6 (15) | |||
| Survival, % (95% CI) | |||||||||
| 5-y OS | 51 (41, 61) | 47 (38, 57) | 28 (18, 37) | 24 (15, 34) | 11 (2, 20) | 3 (0, 8) | |||
| 5-y EFS | 44 (35, 54) | 40 (30, 49) | 26 (16, 35) | 20 (10, 29) | 8 (0, 16) | 0 | |||
| 5-y DFS | 51 (36, 62) | 49 (35, 63) | 41 (26, 56) | 33 (14, 54) | 27 (1, 53) | 0 | |||
. | HIV score 0 . | . | HIV score 1 . | . | HIV score 2-3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic . | ACVBP . | CHOP . | CHOP . | Ld-CHOP . | Ld-CHOP . | VS . | |||
| Median anthracycline DI (range) | 0.91* (0.1-1.1) | 0.98* (0.5-1.2) | 0.96 (0.4-1.8) | 0.96 (0.1-1.4) | 0.97 (0.6-1.2) | NA | |||
| Below 0.80, no. (%) | 32 (29)* | 4 (4)* | 9 (9) | 8 (10) | 5 (10) | NA | |||
| Median cyclophosphamide DI (range) | 0.91 (0.1-1.1) | 0.98 (0.5-1.2) | 0.96 (0.2-1.9) | 0.96 (0.1-1.3) | 0.99 (0.7-1.2) | NA | |||
| Below 0.80, no. (%) | 33 (30)* | 5 (5)* | 8 (8) | 8 (10) | 4 (8) | NA | |||
| G-CSF prophylaxis, no (%) | 97 (89) | 95 (87) | 60 (63) | 42 (51) | 25 (51) | NA | |||
| Toxicity grade 3-4, no. (%) | |||||||||
| Platelets | 50 (46)* | 13 (12)* | 23 (24) | 11 (13) | 1 (22) | 5 (12) | |||
| Leukocytes | 82 (75)* | 39 (36)* | 49 (52)* | 25 (30)* | 20 (41)* | 5 (12)* | |||
| Infection | 28 (26)* | 6 (6)* | 15 (16) | 11 (13) | 12 (24) | 7 (17) | |||
| Mucositis | 21 (19)† | 9 (8)† | 2 (2) | 1 (1) | 1 (2) | 0 (0) | |||
| Response to chemotherapy, no. (%) | |||||||||
| CR/CRu | 66 (61) | 56 (51) | 47 (49)† | 26 (32)† | 10 (20)* | 2 (5)† | |||
| PR | 17 (16) | 16 (15) | 9 (9) | 13 (16) | 6 (12) | 6 (15) | |||
| Survival, % (95% CI) | |||||||||
| 5-y OS | 51 (41, 61) | 47 (38, 57) | 28 (18, 37) | 24 (15, 34) | 11 (2, 20) | 3 (0, 8) | |||
| 5-y EFS | 44 (35, 54) | 40 (30, 49) | 26 (16, 35) | 20 (10, 29) | 8 (0, 16) | 0 | |||
| 5-y DFS | 51 (36, 62) | 49 (35, 63) | 41 (26, 56) | 33 (14, 54) | 27 (1, 53) | 0 | |||
For patients with an HIV score of 0, n = 218 (ACVBP, n = 109; CHOP, n = 109); of 1, n = 177 (CHOP, n = 95; Ld-CHOP, n = 82); of 2-3, n = 90 (Ld-CHOP, n = 49; VS, n = 41).
Ld indicates low dose; DI, dose intensity (administered-planned ratio); CR/CRu, complete response/unconfirmed complete response; CI, confidence interval; DFS, disease-free survival; and NA, not applicable.
Comparison between treatment arms within HIV score strata: P ≤ .01.
Comparison between treatment arms within HIV score strata: P ≤ .05.